Experimental immunotherapy cocktail takes on tough tumors
NCT ID NCT03983954
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. Researchers are also checking if the combo can shrink tumors in certain cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- naptumomab estafenatox and durvalumab (immunotherapy drugs)
- What this could lead to
- If successful, this could lead to a new combination treatment option for several advanced cancers that are hard to treat.
- What could go wrong
- This is a very early Phase 1 trial, so safety and the right dose are still being figured out. It may not work for all cancer types, and side effects from the immune system are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
All India Institute of Medical Sciences
New Delhi, New Delhi, 110029, India
-
Basavatarakam Indo-American Cancer Hospital & Research Institute
Hyderabad, Telangana, 500034, India
-
National Cancer Institute
Jhajjar, Haryana, 124105124105, India
-
PMCH (Pacific Medical College & Hospital)
Udaipur, Rajasthan, 313001, India
-
Rabin Medical Center
Petah Tikva, Israel
-
Rambam Medical Center
Haifa, 3109601, Israel
-
Shalby Hospital
Ahmedabad, Gujarat, 380015, India
-
Sheba Medical Center
Ramat Gan, 52621, Israel
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 6423906, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could a simple scan and blood test outsmart liver cancer?
- Digital peer support: a new weapon against cancer treatment anxiety?
- Could deep breaths before surgery ward off Post-Op confusion?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?